Adult and Pediatric Hemoconcentrators Market| Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• BIO-ENGINEERED STENT MARKET ANALYSIS
• Bio-engineered Stent Market, by Application Type
  (Coronary Artery Disease, Peripheral Arterial
  Disease, Carotid Artery Disease, Renal Artery
  Stenosis, Abdominal Aortic Aneurysm, Thoracic
  Aortic Aneurysm, Others), by Product Type
  (Drug-eluting Stents, Bioabsorbable Stents, and
  Drug-eluting Balloons), by Mode of Delivery
  (Balloon-expandable Stents and Self-expanding
  Stents), by Material Type (Metal-based and
  Polymer-based), by End User (Hospitals Cardiac
  Centers and Ambulatory Surgical Centers, Others),
  and by Region (North America, Latin America,
  Europe, Asia Pacific, Middle East, and Africa) -
  Global Industry Insights and Forecast to 2026
• Bio-engineered stent plays a major role in modern
  healthcare as it expands the blood vessel to
  prevent a blockage of arteries in cardiovascular
  diseases such as coronary heart disease and
  ischemic heart disease.

3

• Figure 1. Global Bio-engineered Stent Market
  Value (US Mn), by Region, 2017

4

• Increasing prevalence of cardiovascular diseases
  such as coronary heart disease and ischemic heart
  disease is expected to propel growth of the
  bio-engineered stent market
• Bio-engineered stent is used in treating blockage
  of coronary and peripheral artery, which is
  related to coronary heart disease, ischemic heart
  disease, and other cardiovascular diseases. High
  prevalence of coronary heart disease, ischemic
  heart disease, and other cardiovascular diseases
  is expected to propel demand for bio-engineered
  stent, which in turn is expected to drive the
  market growth. According to American Heart
  Association, in 2018, around 92.1 million people
  in the U.S. were suffering with some form of
  cardiovascular diseases or the after-effects of
  stroke. Moreover, around 836,546 deaths in the
  U.S. were due to cardiovascular diseases, which
  accounted for 1 in every 3 deaths in the country.
  Direct and indirect costs in the treatment of
  cardiovascular diseases and stroke in the country
  were estimated to be around US 329.7 billion in
  2018, which includes both health expenditures and
  lost productivity.

5

• Similarly, according to World Health Organization
  (WHO), 2015, cardiovascular diseases are the
  highest cause of morbidity and mortality
  worldwide, with around 17.7 million cases
  representing 31 of all worldwide deaths in 2015,
  of which around 6.7 million were due to stroke
  and 7.4 million were due to coronary heart
  disease.
• However, availability of alternatives for the
  treatment of cardiac diseases, product recalls
  and failure, and stringent regulations for
  product approvals are expected to hinder the
  market growth. For instance in November 2017,
  Abbott recall Class 1 Device Recall Absorb
  Bioresorbable Vascular Scaffold (BVS) System, a
  absorbable coronary drug-eluting stent due to
  elevated rates of major adverse events,
  specifically, myocardial infraction and scaffold
  thrombosis when compared to patients treated with
  the Xience metallic drug eluting stent.

6
Figure 2. Global Bio-engineered Stent Market
Share (), by Material, 2018 and 2026

7
Increasing adoption of bio-engineered stents in
North America is expected to bolster the market
growth

• North America holds a dominant position in the
  global bio-engineered stent market, owing to
  rapid growth in geriatric population, increasing
  incidences of cardiac ailments, coronary and
  peripheral artery diseases, and high prevalence
  of obesity in the region. According to World
  Population Prospects, the number of people aged
  80 or over is projected to triple by 2050, from
  137 million in 2017 to 425 million in 2050 in the
  U.S. This age bracket is expected to more than
  double worldwide, increasing from 962 million in
  2017 to 2.1 billion in 2050.
• Moreover, key players in the market are focused
  on receiving regulatory approvals for novel
  products to reduce the burden of blood stream
  infections associated with bio-engineered stents.
  For instance, in September 2018, Biotronik SE
  Co. KG received the U.S. Food and Drug
  Administration (FDA) approval for PK Papyrus
  covered coronary stent system for the treatment
  of acute coronary artery.

8
Key Players

• Major players operating in the global
  bio-engineered stent market include, Medtronic,
  plc., Boston Scientific Corporation, Abbott
  Laboratories, Biotronik SE Co. KG, B. Braun
  Melsungen AG, Terumo Corporation, MicroPort
  Scientific Corporation, Stentys Sao, Meril Life
  Sciences Pvt. Ltd, Vascular Concepts, W. L. Gore
  and Associates, C. R. Bard, Endologix, Inc.,
  Lombard Medical Technologies, Translumina GmbH,
  and JOTEC GmbH.

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/bio-engineered-stent-market-2484

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

12
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/